Trial · NCT03375320
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 8.4 | 95% Confidence Interval 7.6 to 12.7 | months | |
| Progression-free Survival (PFS) | Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 3.9 | 95% Confidence Interval 3.0 to 5.7 | months | |
| Progression-free Survival (PFS) | Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 13.8 | 95% Confidence Interval 9.2 to 18.5 | months | |
| Progression-free Survival (PFS) | Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 4.4 | 95% Confidence Interval 3.0 to 5.9 | months | |
| Overall Survival (OS) | Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 21.9 | 95% Confidence Interval 18.8 to 30.4 | months | |
| Overall Survival (OS) | Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 19.7 | 95% Confidence Interval 14.2 to 30.0 | months | |
| Overall Survival (OS) | Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 40.0 | 95% Confidence Interval 31.3 to NA | months | |
| Overall Survival (OS) | Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 31.1 | 95% Confidence Interval 23.4 to NA | months | |
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 104 | Participants | ||
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 47 | Participants | ||
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 49 | Participants | ||
Number of Patients Experiencing Grade 3+ Adverse Events (AEs) Graded According to the Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 22 | Participants | ||
| Radiographic Response Rate | Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET]) | 7 | Participants | ||
| Radiographic Response Rate | Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET]) | 0 | Participants | ||
| Radiographic Response Rate | Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET]) | 12 | Participants | ||
| Radiographic Response Rate | Arm IIb (Placebo, Pancreatic NET Cohort [pNET]) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03375320/results